70 results
6-K
EX-99.1
TLSA
Tiziana Life Sciences Ltd
25 Apr 24
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
10:00am
Brigham Healthcare System, and Associate Professor of Neurology at Harvard Medical School, stated, “Last week at the American Academy of Neurology annual
6-K
EX-99.1
TLSA
Tiziana Life Sciences Ltd
23 Apr 24
Report of Foreign Private Issuer
7:00am
Medical School and senior neurologist at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System. “The EA program has
6-K
EX-99.1
TLSA
Tiziana Life Sciences Ltd
22 Apr 24
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
10:10am
at Harvard Medical School and senior neurologist at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System. “All 10
6-K
EX-99.1
TLSA
Tiziana Life Sciences Ltd
19 Apr 24
Report of Foreign Private Issuer
7:00am
in Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, and Associate Professor of Neurology
6-K
EX-99.1
srjk7z4uj
18 Apr 24
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
7:00am
6-K
EX-99.1
byv9jyiq
11 Apr 24
Report of Foreign Private Issuer
7:00am
6-K
EX-99.1
f9q9 kpb3
8 Jan 24
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
7:00am
6-K
EX-99.1
nhx9t2t
5 Jan 24
Report of Foreign Private Issuer
7:00am
6-K
EX-99.1
axoi69cgjdpf1hnav2
29 Dec 23
Updated Interim Results for the Six Months Ended 30 June 2023
4:30pm
6-K
EX-99.1
ovmx9v5b 8bju3mlg9
19 Dec 23
Report of Foreign Private Issuer
7:00am
6-K
x9t2 ur9k
30 Nov 23
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
7:08am
6-K
EX-99.1
x3mu300u9qhwoz hjg
30 Nov 23
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
7:08am
6-K
EX-99.1
cwv0p06m0wg8jclk
18 Oct 23
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
7:12am
6-K
EX-99.1
m4lzzuyz ha
16 Oct 23
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
7:00am
6-K
EX-99.1
acb7ms2l7ucalt5l2v
13 Oct 23
Report of Foreign Private Issuer
7:00am
6-K
lf4iv38ual1ox 30lup
26 Sep 23
Report of Foreign Private Issuer
7:00am
6-K
EX-99.1
s5ig f257n36
26 Sep 23
Report of Foreign Private Issuer
7:00am
6-K
EX-99.1
ii5kl f0cf7l
6 Sep 23
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
7:00am
424B5
53z8r77 k5re0
1 Sep 23
Prospectus supplement for primary offering
5:16pm